Vanda Pharmaceuticals Inc. (VNDA), a biopharmaceutical company focused on products for treatment of central nervous system disorders, Friday said that it submitted a New Drug Application or NDA to the FDA for tasimelteon, a circadian regulator. The company is seeking the approval of FDA for Tasimelteon for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.
Non-24 is a serious and rare, circadian rhythm disorder that affects the majority of totally blind individuals who lack light perception and who therefore cannot entrain their master body clock to the 24-hour day.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.